PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Opus Genetics, Inc.

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, active 2024–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
5
Total patents granted
4
CPC technology areas
25.2
Avg claims per patent
-
5-year filing velocity

The verdict

Opus holds 5 US patents across 4 technology areas, rank #49,403 of 50,000 tracked assignees.

#49,403
of 50,000 US assignees by volume
Top 51%
by Innovation Score (34.9/100)
25.2
avg claims per patent

Portfolio overview

Opus Genetics, Inc. has been granted 5 US utility patents between 2024 and 2025, placing Opus Genetics, Inc. at rank #49,403 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 25.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Opus Genetics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Opus sits between Optimum Imaging Technologies Llc (5 patents, rank #49,399) and Orbsurgical Ltd. (5 patents, rank #49,407) - the closest US assignees by grant volume. The composite Innovation Score of 34.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2024 through 2025, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Opus Genetics, Inc.'s 25.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Opus Genetics, Inc. against peers pursuing similar technology classes.

Who files at Opus's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Opus holds 5 patents at rank #49,403, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Opus

By rank, the assignees closest to #49,403 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Opus's primary technology class.

Opus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

35 Top 51% higher than 49% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 20242025 4
USPTO utility patent grants by year · 2024–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.

View data table
Opus Genetics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2024 1 20.0%
2025 4 80.0%

Which technologies does Opus Genetics, Inc. patent most?

Top 4 of 4 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex

Where it ranks

Overall rank by patents

#49,403

Across all tracked assignees

Innovation Score

34.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Opus Genetics, Inc. hold?
Opus Genetics, Inc. holds 5 US granted patents filed between 2024 and 2025, spanning 4 technology areas.
What is Opus Genetics, Inc.'s Innovation Score?
Opus Genetics, Inc. has an Innovation Score of 34.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Opus Genetics, Inc. focus on?
Opus Genetics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 4 patents. The company has filed patents in 4 CPC subclasses total.
Is Opus Genetics, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Opus Genetics, Inc..
What does claim depth mean for Opus Genetics, Inc.'s patents?
Opus Genetics, Inc.'s patents average 25.2 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Opus Genetics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Opus's 5 grants land it in the top 51% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Opus ranks #49,403 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.